HUTCHMED (China) Analyst Ratings
HUTCHMED (China) Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/05/2023 | 231.24% | Cantor Fitzgerald | → $50 | Reiterates | Overweight → Overweight |
| 07/24/2023 | 231.24% | Cantor Fitzgerald | → $50 | Reiterates | Overweight → Overweight |
| 08/09/2022 | 6% | Goldman Sachs | $14 → $16 | Maintains | Neutral |
| 08/02/2022 | -7.25% | Goldman Sachs | $16 → $14 | Maintains | Neutral |
| 09/22/2021 | 204.74% | Goldman Sachs | → $46 | Downgrades | Buy → Neutral |
| 08/03/2021 | 244.48% | Jefferies | → $52 | Initiates Coverage On | → Buy |
| 03/13/2020 | — | Cantor Fitzgerald | Initiates Coverage On | → Overweight | |
| 02/20/2020 | 151.74% | Goldman Sachs | → $38 | Initiates Coverage On | → Buy |
| 11/19/2019 | — | CLSA | Initiates Coverage On | → Buy | |
| 10/23/2019 | — | B of A Securities | Reinstates | → Buy | |
| 03/04/2019 | — | Deutsche Bank | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/05/2023 | 231.24% | 康託·菲茨傑拉德 | →$50 | 重申 | 超重→超重 |
| 07/24/2023 | 231.24% | 康託·菲茨傑拉德 | →$50 | 重申 | 超重→超重 |
| 08/09/2022 | 6% | 高盛 | $14→$16 | 維護 | 中性 |
| 08/02/2022 | -7.25% | 高盛 | $16→$14 | 維護 | 中性 |
| 09/22/2021 | 204.74% | 高盛 | →$46 | 評級下調 | 購買→中性 |
| 08/03/2021 | 244.48% | 傑富瑞 | →$52 | 開始承保 | →購買 |
| 03/13/2020 | - | 康託·菲茨傑拉德 | 開始承保 | →超重 | |
| 02/20/2020 | 151.74% | 高盛 | →$38 | 開始承保 | →購買 |
| 2019年11月19日 | - | 裡昂證券 | 開始承保 | →購買 | |
| 2019年10月23日 | - | B of A證券 | 恢復 | →購買 | |
| 2019/03/04 | - | 德意志銀行 | 開始承保 | →購買 |
What is the target price for HUTCHMED (China) (HCM)?
和黃醫藥(中國)(HCM)的目標價是多少？
The latest price target for HUTCHMED (China) (NASDAQ: HCM) was reported by Cantor Fitzgerald on September 5, 2023. The analyst firm set a price target for $50.00 expecting HCM to rise to within 12 months (a possible 231.24% upside). 2 analyst firms have reported ratings in the last year.
和黃醫藥(中國)(納斯達克代碼：HCM)的最新目標價是由康託·菲茨傑拉德於2023年9月5日報道的。這家分析公司將目標價定為50美元，預計HCM將在12個月內上漲(可能上漲231.24%)。去年有兩家分析公司公佈了評級。
What is the most recent analyst rating for HUTCHMED (China) (HCM)?
分析師對和黃醫藥(中國)的最新評級是多少？
The latest analyst rating for HUTCHMED (China) (NASDAQ: HCM) was provided by Cantor Fitzgerald, and HUTCHMED (China) reiterated their overweight rating.
分析師對和黃醫藥(中國)(納斯達克代碼：HCM)的最新評級由康託·菲茨傑拉德提供，和黃醫藥(中國)重申其增持評級。
When is the next analyst rating going to be posted or updated for HUTCHMED (China) (HCM)?
下一次分析師對和黃醫藥(中國)的評級會在什麼時候發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HUTCHMED (China), and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HUTCHMED (China) was filed on September 5, 2023 so you should expect the next rating to be made available sometime around September 5, 2024.
分析師在進行了廣泛的研究後得出股票評級，這些研究包括查閱公開財務報表，與和黃醫藥(中國飾)的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。和黃醫藥(中國)的上一次評級是在2023年9月5日提交的，所以你應該預計下一次評級將在2024年9月5日左右公佈。
Is the Analyst Rating HUTCHMED (China) (HCM) correct?
分析師對和黃醫藥(中國)的評級正確嗎？
While ratings are subjective and will change, the latest HUTCHMED (China) (HCM) rating was a reiterated with a price target of $0.00 to $50.00. The current price HUTCHMED (China) (HCM) is trading at is $15.10, which is within the analyst's predicted range.
雖然評級是主觀的，會發生變化，但最新的和黃醫藥(中國)(HCM)評級被重申，目標價在0.00美元到50.00美元之間。和黃醫藥(中國)目前的交易價格為15.10美元，在分析師的預測範圍內。